A Review on Parallel Virtual Screening Softwares for High Performance Computers
Natarajan Arul Murugan, Artur Podobas, Davide Gadioli, Emanuele, Vitali, Gianluca Palermo, Stefano Markidis

TL;DR
This review discusses the implementation of parallel algorithms in virtual screening software to accelerate drug discovery processes on high-performance computing systems, focusing on scoring functions, search algorithms, and software performance.
Contribution
It provides a comprehensive overview of parallel virtual screening software, highlighting recent advancements and performance analyses on high-performance computing architectures.
Findings
Parallelization significantly speeds up virtual screening.
Performance varies across different docking software.
High-performance computing enables large-scale drug discovery.
Abstract
Drug discovery is the most expensive, time demanding and challenging project in biopharmaceutical companies which aims at the identification and optimization of lead compounds from large-sized chemical libraries. The lead compounds should have high affinity binding and specificity for a target associated with a disease and in addition they should have favorable pharmacodynamic and pharmacokinetic properties (grouped as ADMET properties). Overall, drug discovery is a multivariable optimization and can be carried out in supercomputers using a reliable scoring function which is a measure of binding affinity or inhibition potential of the drug-like compound. The major problem is that the number of compounds in the chemical spaces is huge making the computational drug discovery very demanding. However, it is cheaper and less time consuming when compared to experimental high throughput…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsComputational Drug Discovery Methods · Protein Degradation and Inhibitors · Statistical Methods in Clinical Trials
